Reason for request
Re-assessment of the actual benefit of third-generation oral contraceptives in response to a request by the Directorate-General for Health dated 27 December 2011.
Clinical Benefit
| Insufficient |
taking into account both the increased risk of venous thromboembolic events and the lack of demonstrated benefit in terms of clinical safety in women exposed to third-generation oral contraceptives compared with second- or first-generation oral contraceptives, the actual benefit of these proprietarymedicinal products must be regarded as insufficient for reimbursement by National Health Insurance.
|
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
hHGCxj0zaqY1HbTm